CN107406419B - Pet显像剂 - Google Patents

Pet显像剂 Download PDF

Info

Publication number
CN107406419B
CN107406419B CN201680016753.9A CN201680016753A CN107406419B CN 107406419 B CN107406419 B CN 107406419B CN 201680016753 A CN201680016753 A CN 201680016753A CN 107406419 B CN107406419 B CN 107406419B
Authority
CN
China
Prior art keywords
methyl
pharmaceutically acceptable
acceptable salt
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680016753.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN107406419A8 (zh
CN107406419A (zh
Inventor
Y·奥贝松
E·布里亚尔
B·奥伯豪泽尔
D·罗格朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN107406419A publication Critical patent/CN107406419A/zh
Publication of CN107406419A8 publication Critical patent/CN107406419A8/zh
Application granted granted Critical
Publication of CN107406419B publication Critical patent/CN107406419B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nuclear Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201680016753.9A 2015-01-20 2016-01-20 Pet显像剂 Active CN107406419B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105336P 2015-01-20 2015-01-20
US62/105,336 2015-01-20
PCT/IB2016/050276 WO2016116875A1 (en) 2015-01-20 2016-01-20 Pet imaging agents

Publications (3)

Publication Number Publication Date
CN107406419A CN107406419A (zh) 2017-11-28
CN107406419A8 CN107406419A8 (zh) 2018-01-12
CN107406419B true CN107406419B (zh) 2020-09-11

Family

ID=55300733

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680016753.9A Active CN107406419B (zh) 2015-01-20 2016-01-20 Pet显像剂

Country Status (12)

Country Link
US (2) US10450298B2 (cg-RX-API-DMAC7.html)
EP (1) EP3247706B1 (cg-RX-API-DMAC7.html)
JP (2) JP6723264B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170103960A (cg-RX-API-DMAC7.html)
CN (1) CN107406419B (cg-RX-API-DMAC7.html)
AU (1) AU2016209906A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017015455A2 (cg-RX-API-DMAC7.html)
CA (1) CA2974311A1 (cg-RX-API-DMAC7.html)
EA (1) EA201791643A1 (cg-RX-API-DMAC7.html)
ES (1) ES2828715T3 (cg-RX-API-DMAC7.html)
MX (1) MX2017009452A (cg-RX-API-DMAC7.html)
WO (1) WO2016116875A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016209906A1 (en) 2015-01-20 2017-08-03 Novartis Ag PET imaging agents
TWI809597B (zh) * 2020-12-16 2023-07-21 美商美國禮來大藥廠 預靶向造影劑

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0224917D0 (en) * 2002-10-25 2002-12-04 Novartis Ag Organic compounds
WO2005043300A2 (en) 2003-10-20 2005-05-12 Empirix, Inc. Computer language interpretation and optimization for server testing
US20070259863A1 (en) 2004-04-28 2007-11-08 Icos Corporation Arylphenylamino-,Arylphenylamide-, and Arylphenylether-Sulfide Derivatives
WO2005121094A1 (en) 2004-06-09 2005-12-22 Pfizer Limited Piperazine and piperidine derivatives as anti-hiv-agents
CN101429161A (zh) * 2008-12-05 2009-05-13 常熟理工学院 Pet显像剂前体异喹啉甲酰胺衍生物的合成方法
JP5767205B2 (ja) * 2009-04-02 2015-08-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ オートタキシン阻害剤としての複素環式化合物
WO2012020567A1 (en) 2010-08-09 2012-02-16 Raqualia Pharma Inc. Acyl piperazine derivatives as ttx-s blockers
US9000025B2 (en) * 2010-08-20 2015-04-07 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
EA201492223A1 (ru) * 2012-06-13 2015-03-31 Ф. Хоффманн-Ля Рош Аг Новые диазаспироциклоалканы и азаспироциклоалканы
SG11201504633PA (en) 2012-12-19 2015-07-30 Novartis Ag Autotaxin inhibitors
ES2742077T3 (es) 2013-07-18 2020-02-13 Novartis Ag Inhibidores de autotaxina que comprenden un núcleo de anillo heteroaromático de bencil-amida cíclica
AU2016209906A1 (en) 2015-01-20 2017-08-03 Novartis Ag PET imaging agents

Also Published As

Publication number Publication date
BR112017015455A2 (pt) 2018-01-23
US20180273509A1 (en) 2018-09-27
EP3247706A1 (en) 2017-11-29
WO2016116875A1 (en) 2016-07-28
JP2018511648A (ja) 2018-04-26
CN107406419A8 (zh) 2018-01-12
CN107406419A (zh) 2017-11-28
MX2017009452A (es) 2017-11-08
KR20170103960A (ko) 2017-09-13
US20200017474A1 (en) 2020-01-16
JP2020158532A (ja) 2020-10-01
JP6723264B2 (ja) 2020-07-15
AU2016209906A1 (en) 2017-08-03
US10450298B2 (en) 2019-10-22
US10865195B2 (en) 2020-12-15
CA2974311A1 (en) 2016-07-28
EA201791643A1 (ru) 2017-11-30
ES2828715T3 (es) 2021-05-27
EP3247706B1 (en) 2020-07-08

Similar Documents

Publication Publication Date Title
US8858911B2 (en) Phosphodiesterase 1-targeting tracers and methods
JP5347164B2 (ja) ニトロ−イミダゾール低酸素造影剤
JP7752201B2 (ja) 放射性標識カンナビノイド受容体２リガンド
CN101687780A (zh) 用于使心脏神经支配成像的配体
BRPI0808503B1 (pt) Composto, uso de um composto, e, composição farmacêutica
CN107406419B (zh) Pet显像剂
WO2005009479A1 (en) Radiolabeled cannabinoid-1 receptor modulators
JP5196561B2 (ja) 核医学診断用医薬
HK40089266A (zh) 放射性标记的大麻素受体2配体
JP6041751B2 (ja) スチリルピリジン誘導体化合物
CN120136958A (zh) Fap靶向放射性药物
HK40044011B (en) Radiolabeled cannabinoid receptor 2 ligand
JP2014218454A (ja) スチリルピリジン誘導体化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CI02 Correction of invention patent application
CI02 Correction of invention patent application

Correction item: Classification number

Correct: C07D 401/12(2006.01)|C07D 413/12(2006.01)|C07B 59/00(2006.01)|A61K 31/496(2006.01)|A61K 51/04(2006.01)|A61B 6/00(2006.01)|A61B 8/00(2006.01)

False: A99Z 99/00(2006.01)

Number: 48-01

Page: The title page

Volume: 33

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant